Estimaciones de analistas de Wall Street para ProPhase Labs, Inc. (PRPH): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 1 |
| Mantener | 1 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 2 |
| Calificación media (1-5) | 0.50 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-16 | $2.05 | ||
| 2026-08-19 | $-0.22 | ||
| 2026-06-30 | $-0.43 | $-1.20 | +64.2% |
| 2026-04-14 | $-0.87 | $-1.20 | +27.5% |
| 2025-11-19 | $-1.60 | $-1.10 | -45.5% |
| 2025-08-13 | $-1.10 | $-1.50 | +26.7% |
| 2025-05-20 | $-1.20 | $-1.80 | +33.3% |
| 2025-03-31 | $-1.86 | $-0.24 | -675.0% |
Ratios de valoración
| Precio / Valor contable | -0.06 |
| EV / EBITDA | -1.31 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $21.0M | $9.9M | $13.1M | $9.9M | $14.5M | $79.0M | $122.6M | $44.4M | $6.8M | $4.3M |
| Coste de Ventas | $10.9M | $7.9M | $8.3M | $7.3M | $9.9M | $46.2M | $52.0M | $28.1M | $6.9M | $3.0M |
| Beneficio Bruto | $10.1M | $1.9M | $4.8M | $2.6M | $4.6M | $32.8M | $70.7M | $16.2M | -$150000 | $1.4M |
| I+D | $575000 | $431000 | $398000 | $332000 | $633000 | $520000 | $652000 | $1.4M | $594000 | $107000 |
| Generales y Administrativos | $12.1M | $5.5M | $6.0M | $5.5M | $7.9M | $22.5M | $46.4M | $34.5M | $37.9M | $19.3M |
| Gastos Operativos | $12.7M | $5.9M | $6.4M | $5.9M | $8.6M | $23.0M | $47.1M | $37.9M | $38.5M | $19.4M |
| Beneficio Operativo | -$2.7M | -$4.0M | -$1.6M | -$3.2M | -$4.0M | $9.8M | $23.6M | -$21.6M | -$38.6M | -$18.0M |
| EBITDA | -$3.4M | -$3.7M | -$1.3M | -$2.7M | -$1.5M | $11.4M | $28.7M | -$14.8M | -$32.3M | -$11.4M |
| Gastos por Intereses | $213000 | $54000 | 0 | 0 | $295000 | $1.1M | $764000 | $1.3M | $3.4M | $6.9M |
| Beneficio Antes de Impuestos | -$2.9M | -$3.7M | -$1.5M | -$3.1M | -$2.3M | $5.3M | $22.9M | -$22.4M | -$42.3M | -$23.4M |
| Impuestos | $212000 | -$18.0M | $103000 | 0 | $12000 | -$968000 | $4.4M | -$6.0M | $7.2M | 0 |
| Beneficio Neto | -$2.9M | $41.8M | -$1.7M | -$3.1M | -$2.1M | $6.3M | $18.5M | -$16.8M | -$53.4M | -$14.7M |
| BPA | $-1.70 | $26.10 | $-1.50 | $-2.60 | $-2.00 | $4.10 | $11.70 | $-9.80 | $-26.10 | $-1.74 |
| BPA Diluido | $-1.70 | $25.90 | $-1.50 | $-2.60 | $-2.00 | $4.00 | $10.20 | $-9.80 | $-26.10 | $-1.74 |
| Acciones en Circulación (Diluidas) | $1.7M | $1.6M | $1.1M | $1.2M | $1.2M | $1.8M | $1.9M | $1.7M | $1.9M | $8.5M |
Precio
| Precio | $0.01 |
| Capitalización | $0M |
| Bolsa | OTC |
| País | US |
Empresas relacionadas: ADAP · AEMD · ALUR · AYTU · BFRI · CODX · ERNA
Explorar sector: Healthcare · Medical - Pharmaceuticals
Más secciones de PRPH: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones